Chemotherapy-induced Peripheral Neuropathy (CIPN)
Conditions
Brief summary
This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with Albumin-paclitaxel chemotherapy regimen.
Detailed description
This study was randomly divided into two groups at a ratio of 1:1, with 176 subjects in each group. All patients received GM1/ placebo treatment + chemotherapy. The main purpose of this study is to evaluate the effectiveness of GM1 in preventing peripheral neuropathy caused by albumin-paclitaxel chemotherapy. The primary endpoint was the end of GM1 treatment in cycle 4 (C4D21), and the proportion of patients whose FACT/GOG-Ntx score changed by more than 12 points from baseline.
Interventions
DRUGGM1
GM1 was administered intravenously one day before the administration of each cycle of chemotherapy. The experimental group was given 400 mg of GM1 injection. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
DRUGPlacebo
Placebo was administered intravenously one day before the administration of each cycle of chemotherapy. The control group was given placebo. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Voluntarily sign the informed consent form; * Age: 18 to 75 years old; * Female patients with breast cancer confirmed byhistological and/or cytological diagnostic basis for breast cancer and are intended to receive adjuvant/neoadjuvant therapy with Albumin paclitaxel regimens; * ECOG: 0-1 * Adequate organ function level * Glycated hemoglobin (HbA1c) \< 7.0%; * For women of childbearing potential: use effective contraceptive measures for contraception from the date of signing the informed consent form until 30 days after the last use of the investigatory drug. * Patients can accurately record or express the occurrence and severity of peripheral neuropathy through questionnaires.
Exclusion criteria
* Grade ≥1 peripheral neuropathy (CTCAE grade ≥1) or any of the first 4 items of FACT/GOG-Ntx ≥1; * There are risk factors for peripheral neuropathy (excluding peripheral neuropathy caused by chemotherapy). * History of another malignant tumors (except breast cancer) * Symptoms such as muscle pain in the limbs that interfere with the evaluate of peripheral neuropathy; * Uncontrolled cardiovascular and cerebrovascular system diseases or hypertension * Active infections that require systematic treatment, including bacteria, fungi or viruses, within one week before first study drug use; Or infectious diarrhea occurred within 4 weeks before the first study drug use; * Hereditary abnormal glycolipid metabolism, HIV infection or known Acquired Immune Deficiency Syndrome (AIDS); Positive syphilis antibody, active hepatitis B, active hepatitis C
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FACT/GOG-Ntx scores with a change of more than 12 points from the baseline | At the end of Cycle 4 (21day/Cycle） | The proportion of those whose FACT/GOG-Ntx score changed by more than 12 points from the baseline at the end of the fourth cycle of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of grade ≥2 (CTCAE) CIPN | At the end of Cycle 4 (21day/Cycle）,At the end of Cycle 6 (21day/Cycle） | The incidence of grade ≥2 (CTCAE) CIPN |
| Assessment of functional impairment | At the end of Cycle 4 (21day/Cycle）,At the end of Cycle 6 (21day/Cycle） | Vibration sensitivity test and Grooved pegboard test |
| Assessment of Quality of Life | At the end of Cycle 4 (21day/Cycle）,At the end of Cycle 6 (21day/Cycle） | Assessment of Quality of Life（QLQ C30） |
| FACT/GOG-Ntx scores with a change of more than 12 points from the baseline | At the end of Cycle 6 (21day/Cycle） | The proportion of those whose FACT/GOG-Ntx score changed by more than 12 points from the baseline at the end of the sixth cycle of treatment |
Countries
China
Contacts
Primary ContactZeFei Jiang, Chief Physician
Outcome results
None listed